First percutaneous coronary intervention. (a) Coronary angiography showed 90% stenosis in the mid-right coronary artery; (b) stenting was performed using a everolimus-eluting stent (XIENCE PRIME; Abbott Vascular); (c) and then postdilating with a TREK balloon (4 × 8 mm). (d) The procedure was completed with good results.
Case report
In the literature, several cases have been reported of coronary spasms after the placement of a first-generation drug-eluting stent; no reports have been published of spasms in relation to a second-generation drug-eluting stent designed to decrease neointimal response and more rapid re-endothelialization [1] .
A 55-year-old man was admitted to our hospital with acute chest pain. He was a smoker and had a history of hypercholesterolemia. Coronary angiography (CAG) showed 90% stenosis in the mid-right coronary artery (RCA) and a moderate occlusion of the left anterior descendant artery, for which stenting was performed using a everolimus-eluting (XIENCE PRIME; Abbott Vascular, Temecula, California, USA) stent (3.5 × 28 mm; Abbott Vascular) and then postdilating with a TREK balloon (4 × 8 mm) (maximum diameter > 4.25 mm) (Fig. 1) . He was discharged after 1 day of observation. However, the patient had similar complaints of chest pain 3 days later; therefore, he was again admitted to our hospital. ECG showed transient ST elevation of greater than 2 mm in lead II-III-aVF. We performed CAG without an exercise test and without stopping oral vasoactive agents before CAG because we were concerned about the possibility of unstable angina because of the presence of resting chest pain. CAG showed severe vasospasm in the proximal RCA at the proximal edge of the previously implanted stent; no other significant lesions were present to account for the resting chest pain.
The spasm was completely relieved by an intracoronary nitroglycerine injection during CAG, and also the chest pain and the ECG changes (Fig. 2) . CAG also showed slow flows (TIMI II). The patient had taken aspirin, ticagrelor, rosuvastatina, and metoprolol. Because coronary spasm was found, a calcium channel antagonist (nifedipine 30 mg/day) was added to antiangina medication after recovery. On follow-up, the patient has had no recurrence of chest pain at rest.
The rates of angiographic in-stent restenosis, target lesion, and target vessel revascularization are significantly lower with drug-eluting stents. However, the specter of serious, rare idiosyncratic reactions to stents, particularly drugeluting stents with polymer and active pharmacologic constituents, remains a concern [2] . To date, documented vascular compatibility issues include rare hypersensitivity reactions and persistent abnormal vasomotor responses in the drug-eluting stented vessel. If the drug-eluting stent system is the cause of the spasm, it could potentially be a reaction to the stainless-steel stent platform, the polymers, or the medications released [3] . It is unlikely to be the stainless-steel platform, given the large number of baremetal stents used worldwide and the paucity of similar reports of diffuse spasm. Endothelial dysfunction may be because of a direct toxic effect of the released drug, an acute or delayed hypersensitivity reaction (Kounis syndrome) to the drug or the polymer, or impaired or absent re-endothelialization after percutaneous coronary intervention barotraumas [4] . In particular, the RCA appears to be affected by the spasm. In our case, the entire RCA, upstream and downstream of the drug-eluting stent, is spastic. The cause of this particular sensitivity is not yet clear. Currently, vasospastic angina is treated with a combination of different classes of calcium channel blockers and nitrates.
